Curetis GmbH

General information
Curetis GmbH
Max-Eyth-Str. 42
71088 Holzgerlingen, Baden-W├╝rttemberg
Germany

Contact person: Olivier Schacht, Chief Executive Officer
Company main phone: +49 (7031) 4919510
Website:  www.curetis.com
Year founded:2007
Source of foundation:Independent foundation
Corporate description / mission:
Curetis GmbH, is a molecular diagnostics company based in Holzgerlingen near Stuttgart, Germany, and a wholly-owned subsidiary of OpGen Inc. Curetis GmbH develops and commercializes molecular diagnostic products, with the goal to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients.
State of ownership: Subsidiary
Headquarters: No
IPO (year): 2015
Remarks on ownership / listings
Curetis GmbH and its subsidiaries Curetis USA Inc. and Ares Genetics GmbH became wholly owned by OpGen, Inc. in April 2020.

Delisted from Euronext on 06/05/2020.
Categorization
Sector:
  • Biotechnology - R&D Services
Subsector:
  • Diagnostic instrumentation
Business model:
  • Manufacturer
  • Supplier / Distributor
Customer segments:
  • Hospitals
  • Large biotech & big pharma
Summary Products / Services / Technologies
Number of Biotech Products
On the market:5
Number of Medtech Products
In development:3
On the market:4
Description of products:
Unyvero Molecular Diagnostic Platform with: Unyvero L4 Lysator, Unyvero A50 Analyzer and Unyvero C8 Cockpit. Currently there are 5 different panels for hospitalized pneumonia, implant & tissue, intra-abdominal, blood culture and urinary tract infections to rapidly detect pathogens and antibiotic resistances of severe infectious diseases.
X